Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)

被引：0
|
作者：
Hernando Cubero, J. [1 ]
Taberna Sanz, M. [2 ]
Carmona Bayonas, A. [3 ]
Iglesias, L. [4 ]
Grande, E. [5 ]
Trigo Perez, J. M. [6 ]
Grau, J. J. [7 ]
Lopez-Picazo, J. M. [8 ]
Castelo, B. [9 ]
Alonso Gordoa, T. [10 ]
Lorenzo, I. [11 ]
Casado Herraez, A. [12 ]
Ugidos, L. [13 ]
Munarriz, J. [14 ]
Lavernia, J. [15 ]
Capdevila, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[2] Hosp Duran & Reynals, ICO, Med Oncol, Lhospitalet De Llobregat, Spain
[3] Hosp Univ Morales Meseguer, Hematol & Med Oncol, Murcia, Spain
[4] Univ Hosp 12 Octubre, Oncol, Madrid, Spain
[5] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
[6] Hosp Univ Virgen de la Victoria, Med Oncol, Malaga, Spain
[7] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[8] Clin Univ Navarra, Med Oncol, Pamplona, Spain
[9] Hosp Univ La Paz, Med Oncol, Madrid, Spain
[10] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain
[11] Complejo Hosp Univ Vigo, Med Oncol, Vigo, Spain
[12] Hosp Clin Univ San Carlos, Dept Med Oncol, Madrid, Spain
[13] HM San Chinarro, Med Oncol, Madrid, Spain
[14] Hosp Gen Castellon, Med Oncol, Castellon de La Plana, Spain
[15] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1872TiP
引用
收藏
页码：759 / 759
页数：1
相关论文
共 50 条
  • [21] NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Audenet, F.
    Borchiellini, D.
    Huillard, O.
    Barthelemy, P.
    Pouessel, D.
    Flechon, A.
    Blons, H.
    Sautes-Fridman, C.
    Sun, C-M.
    Verkarre, V.
    Pallet, N.
    Mejean, A.
    Rouabah, M.
    Helali, I.
    Elaidi, R-T.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] PAZONET: A PHASE II TRIAL OF PAZOPANIB AS A SEQUENCING TREATMENT IN PROGRESSIVE METASTATIC NEUROENDOCRINE TUMORS (NETS) PATIENTS (PTS), ON BEHALF OF THE SPANISH TASK FORCE FOR NETS (GETNE)
    Grande, E.
    Castellano, D.
    Garcia-Carbonero, R.
    Teule, A.
    Duran, I.
    Fuster, J.
    Sevilla, I.
    Escudero, P.
    Sastre, J.
    Casanovas, O.
    Ortega, L.
    Earl, J.
    Diez, J. J.
    de Velasco, G.
    Longo, F.
    Navarro, A.
    Pachon, V.
    Carrato, A.
    Salazar, R.
    Capdevila, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 377 - 377
  • [23] Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNE-T1914)
    Capdevila Castillon, J.
    Molina-Cerrillo, J.
    Benavent Vinuales, M.
    Garcia-Carbonero, R.
    Teule, A.
    Custodio, A.
    Jimenez-Fonseca, P.
    Lopez, C.
    Hierro, C.
    Carmona-Bayonas, A.
    Martinez-Trufero, J.
    Llanos, M.
    Sevilla, I.
    Hernando, J.
    Alonso-Gordoa, T.
    Gallego Jimenez, I.
    Gallego, J.
    Anton Pascual, B.
    Grande, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S498 - S498
  • [24] Adverse Event Profiles and Time to Onset and Resolution with Tremelimumab ( T) plus Durvalumab (D) in Patients with Unresectable Hepatocellular Carcinoma (uHCC) in the Phase 3 HIMALAYA Trial
    De Toni, E. M.
    Sangro, B.
    Chan, S. L.
    Kudo, M.
    Kelley, R. K.
    -K, Kang Y.
    Rimassa, L.
    Varela, M.
    Dayyani, F.
    Makowsky, M.
    Marcovitz, M.
    Mccoy, C. L.
    Negro, A.
    Abou-Alfa, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 240
  • [25] PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer
    Evrard, Camille
    Louvet, Christophe
    Hajbi, Farid E. L.
    Fiore, Frederic D., I
    Malicot, Karine L. E.
    Aparicio, Thomas
    Bouche, Olivier
    Laurent-Puig, Pierre
    Bibeau, Frederic
    Lecomte, Thierry
    Lievre, Astrid
    Guimbaud, Rosine
    Kim, Stefano
    Zaanan, Aziz
    Sokol, Harry
    Chibaudel, Benoist
    Desrame, Jerome
    Pierre, Sabrina
    Gonzalez, Daniel
    Lepage, Come
    Tougeron, David
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (04) : 420 - 426
  • [26] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
    Powles, Thomas
    van der Heijden, Michiel S.
    Castellano, Daniel
    Galsky, Matthew D.
    Loriot, Yohann
    Petrylak, Daniel P.
    Ogawa, Osamu
    Park, Se Noon
    Lee, Jae-Lyun
    De Giorgi, Ugo
    Bogemann, Martin
    Bamias, Aristotelis
    Eigl, Bernhard J.
    Gurney, Howard
    Mukherjee, Som D.
    Fradet, Yves
    Skoneczna, Iwona
    Tsiatas, Marinos
    Novikov, Andrey
    Suarez, Cristina
    Fay, Andre P.
    Duran, Ignacio
    Necchi, Andrea
    Wildsmith, Sophie
    He, Philip
    Angra, Natasha
    Gupta, Ashok K.
    Levin, Wendy
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2020, 21 (12): : 1574 - 1588
  • [27] NEMIO: A randomized phase I-II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) plus durvalumab plus /- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
    Thibault, C.
    Elaidi, R. T.
    Pouessel, D.
    Flechon, A.
    Borchiellini, D.
    Barthelemy, P.
    Huillard, O.
    Rouabah, M.
    Braychenko, E.
    Helali, I.
    Audenet, F.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S723 - S723
  • [28] Durvalumab (D) plus /- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial
    Thibault, C.
    Bennamoun, M.
    Flechon, A.
    Gravis, G.
    Pouessel, D.
    Combe, P-F.
    Borchiellini, D.
    Loriot, Y.
    Laguerre, B.
    Barthelemy, P.
    Goupil, M. Gross
    Helissey, C.
    Huillard, O.
    Cancel, M.
    Campedel, L.
    Audenet, F.
    Belhouari, H.
    Kotti, S.
    Tran, Y.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1202 - S1202
  • [29] PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D plus T) versus standard of care chemotherapy (SoC)
    Bellmunt, J.
    Powles, T. B.
    Van der Heijden, M. S.
    Galsky, M. D.
    He, P.
    Wang, Z.
    Xiao, F.
    Jones, F.
    Scott, M.
    Walker, J.
    Angra, N.
    Gupta, A.
    Drakaki, A.
    Kimura, G.
    Mizokami, A.
    Wildsmith, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S716 - S717
  • [30] Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
    Garcia del Muro, Xavier
    Valderrama, Begona P.
    Medina, Ana
    Andres Cuellar, M.
    Etxaniz, Olatz
    Girones Sarrio, Regina
    Jose Juan-Fita, Maria
    Ferrer, Ferran
    Miras Rodriguez, Isabel
    Lendinez-Cano, Guillermo
    de Haro Piedra, Roberto
    Candal Gomez, Arturo
    Chantada Abal, Venancio
    Salvador Villa, Oscar Buisan
    Luis Pontones, Jose
    Collado, Erica
    Dominguez-Escrig, Jose L.
    Murria, Yashmina
    Vigues, Francesc
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345